CVM - CEL-SCI Corporation

NYSE American - NYSE American Delayed Price. Currency in USD
16.49
-0.56 (-3.28%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close17.05
Open16.96
Bid16.70 x 3000
Ask16.82 x 1100
Day's Range16.03 - 17.05
52 Week Range2.37 - 17.80
Volume938,114
Avg. Volume818,778
Market Cap600.073M
Beta (5Y Monthly)2.93
PE Ratio (TTM)N/A
EPS (TTM)-0.88
Earnings DateFeb 09, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateAug 27, 1996
1y Target Est18.00
  • Business Wire

    CEL-SCI Corporation Reports First Quarter Fiscal 2020 Financial Results

    CEL-SCI Corporation reports first quarter fiscal 2020 financial results.

  • Business Wire

    CEL-SCI to Present at 2020 BIO CEO & Investor Conference

    CEL-SCI to present at 2020 BIO CEO & Investor Conference.

  • Business Wire

    CEL-SCI to Participate in Upcoming Investor Conferences

    CEL-SCI to participate in upcoming investor conferences.

  • Business Wire

    CEL-SCI Announces Full Exercise of Over-allotment Option by Aegis Capital Corp.

    CEL-SCI announces full exercise of over-allotment option by Aegis Capital Corp.

  • Company News For Dec 26, 2019
    Zacks

    Company News For Dec 26, 2019

    Companies In The News Are: SSNT, NLNK, CVM, AXE

  • Hedge Funds Are Buying CEL-SCI Corporation (CVM)
    Insider Monkey

    Hedge Funds Are Buying CEL-SCI Corporation (CVM)

    Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]

  • ACCESSWIRE

    CEL-SCI Corporation to Present at The LD Micro Main Event (XII)

    VIENNA, VA / ACCESSWIRE / December 6, 2019 / CEL-SCI Corporation (NYSE American:CVM), a Phase 3 cancer immunotherapy company, today announced that it will be presenting at the 12th annual LD Micro Main Event on Tuesday, December 10, 2019 at 2:00 PM PST or 5:00 PM EST. The Chief Executive Officer, Geert Kersten, will be presenting and meeting with investors. To access the live webcast and subsequent archived recordings for the presentation, please visit the Investor Relations section of the Company's website at https://cel-sci.com/new-investor-information/.

  • CVM: IDMC Nod & Target Price Raise
    Zacks Small Cap Research

    CVM: IDMC Nod & Target Price Raise

    By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT The Last Review? CEL-SCI Corporation (NYSE:CVM) today announced its second Independent Data Monitoring Committee (IDMC) review this year for the IT MATTERS Phase III Multikine study for head and neck cancer. We believe that the longer than expected duration of the trial combined with the IDMC recommendation to continue its

  • CVM: A Focus on LEAPS
    Zacks Small Cap Research

    CVM: A Focus on LEAPS

    By John Vandermosten, CFA NYSE:CVM While CEL-SCI (NYSE:CVM) has experienced outstanding performance over the last several quarters due to the anticipated readout of Multikine in the IT-MATTERS clinical trial, the company also has a platform technology in development that has impressive potential in treating a number of human diseases. This platform is known as the Ligand

  • These 3 Biotech Stocks Skyrocketed Last Week -- Are They Buys Now?
    Motley Fool

    These 3 Biotech Stocks Skyrocketed Last Week -- Are They Buys Now?

    These stocks were huge winners last week. But can their momentum continue?

  • Zacks Small Cap Research

    CVM: No Free Samples on Facility Tour

    In late May 2019, Zacks was treated to an onsite tour of CEL-SCI’s (CVM) 73,000 square foot manufacturing facility in Elkridge, Maryland. As we drove to the industrial park southwest of Baltimore, we came upon CEL-SCI’s facility, nestled among warehouses and light manufacturing enterprises. With multiple delivery bays and administrative offices up front, we entered to meet with Chief Scientific Officer Dr. Eyal Talor who introduced us to the staff and provided background on the facility in preparation for our walk through.

  • Benzinga

    The Companies Set To Join The Russell Index July 1

    OncoCyte Corporation (NYSE: OCX ) is set to join the Russell 2000, Russell 3000 and Russell Microcap Indexes July 1. The Russell 3000 Index is a capitalization-weighted stock market index maintained by ...

  • Business Wire

    CEL-SCI Corporation Set to Join Russell 3000® Index

    CEL-SCI Corporation (NYSE American: CVM) is set to join the broad-market Russell 3000® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective after the US market opens on July 1, according to a preliminary list of additions posted June 7. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 10, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes.

  • Business Wire

    CEL-SCI Corporation to Present at the 9th Annual LD Micro Invitational

    CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that it will be presenting at the 9th annual LD Micro Invitational on Tuesday, June 4th at 10:40 a.m. PT. Geert Kersten, Chief Executive Officer of CEL-SCI, will be giving the presentation. Mr. Kersten’s presentation will be webcast and available in the Investor Relations section of the Company's website at https://cel-sci.com/new-investor-information/.